Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
GC Biopharma Enters Phase 2 for Homegrown mRNA Vaccine, Targets 2028 Rollout
1+ day, 21+ hour ago (213+ words) First Patient Dosing to Begin This Year, Phase 3 IND Filing Planned for Next Year Domestic Vaccine Self-Sufficiency and Proprietary mRNA-LNP Platform Sovereignty GC Biopharma said on the 11th that the Ministry of Food and Drug Safety had approved the investigational new…...
Oxford University cancer vaccine firm celebrates $500K USD investment
5+ day, 7+ hour ago (442+ words) An Oxford University cancer firm is celebrating a $500K investment from one of its shareholders, which will allow it to continue its research. Dr Tony Coombs, chair of Oxford Vacmedix UK Limited, a company based at Oxford Science Park, said he…...
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
1+ week, 16+ hour ago (433+ words) The FDA approved a therapy from Revolution Medicines that slows a cancer that kills seven of out eight patients within five years The excitement surrounding Moderna and Merck ’s personalized mRNA cancer vaccine added more than $50 billion in combined market…...
MRNA Looks 503.4% Overvalued on GF Value™
1+ week, 10+ hour ago (304+ words) On September 05, 2026, the healthcare sector surged 4.91% in August, outpacing the S&P 500’s 2.68% gain, driven largely by biotechnology breakthroughs. Moderna Inc (NASDAQ: MRNA) led the charge with a remarkable 156.0% rally following promising interim results from its mRNA cancer vaccine trial. The…...
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance
1+ week, 15+ hour ago (913+ words) Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp rally in oncology sequencing and diagnostics stocks. Tempus AI, positioned as a potential sequencing partner, surged 24%, while its acquisition of Personalis has come…...
Transgene jumps 20% on positive cancer vaccine data in early trial
1+ week, 2+ day ago (191+ words) Sept 3 (Reuters) – Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data from other personalised cancer-vaccine programmes…...
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS?? (Anthrax Vaccine Adsorbed, Adjuvanted)
1+ week, 4+ day ago (637+ words) Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) marketscreener.com...
GSK Plans Late-stage Trial for Flu Vaccine After Positive Phase 2 Results
1+ week, 4+ day ago (44+ words) Published on 09/01/2026 at 02:43 am EDT A No to BMS can open doors for a Yes to GSK August 12, 2026 at 08:55 am EDT Goldman Sachs still cautious about GSK GSK: shareholders urge company to step up reinvention...
Inside Moderna and Merck's cancer vaccine breakthrough
1+ week, 6+ day ago (91+ words) Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead. Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on Aug. 13 when…...
Melanoma Vaccine Data Breakthrough: Moderna Receives Fifth Analyst Upgrade in Five Days — BigGo Finance
2+ week, 1+ day ago (391+ words) U.S. biotech giant Moderna (MRNA) continues to ride a wave of momentum from clinical data on its melanoma mRNA cancer vaccine, prompting a notable shift in Wall Street analyst sentiment. Argus Research this week upgraded Moderna from "Hold" to "Buy," becoming…...